When using both CGP (TMB-High) and PD-L1 IHC (TPS ≥ 1), 54.7% (581/1063) of the patients with NSCLC-BM were eligible for pembrolizumab monotherapy based on PD-L1 IHC, and 56.9% (605/1063) were eligible for pembrolizumab monotherapy based on TMB-High status, and 32.1% (341/1063) of patients positive for both PD-L1 IHC and TMB-High (Fig. 3A). Here, CD274 is linked to non-small cell lung carcinoma.